| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42001719 | EBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS10006549 | HBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS10008067 | HBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS10008068 | HBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30003991 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30079115 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30087748 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30081211 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30081546 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30082146 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | EGFR |
|---|---|
| DrugBank ID | DB00530 |
| Drug Name | Erlotinib |
| Target ID | BE0000767 |
| UniProt ID | P00533 |
| Regulation Type | antagonist |
| PubMed IDs | 12498017; 12517254; 12814826; 12820772; 12840797; 11752352 |
| Citations | Kim TE, Murren JR: Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs. 2002 Sep;3(9):1385-95.@@Laird AD, Cherrington JM: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs. 2003 Jan;12(1):51-64.@@Delbaldo C, Faivre S, Raymond E: [Epidermal growth factor inhibitors]. Rev Med Interne. 2003 Jun;24(6):372-83.@@Bulgaru AM, Mani S, Goel S, Perez-Soler R: Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev Anticancer Ther. 2003 Jun;3(3):269-79.@@Akita RW, Sliwkowski MX: Preclinical studies with Erlotinib (Tarceva). Semin Oncol. 2003 Jun;30(3 Suppl 7):15-24.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational |
| Direct Classification | Quinazolinamines |
| SMILES | COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2 |
| Pathways | Erlotinib Action Pathway |
| PharmGKB | PA134687924 |
| ChEMBL | CHEMBL553 |
